Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FABP1 | P07148 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | FOS | P01100 | 2/20 | 0.38 |
| ▸ | JUN | P05412 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18304472 | 0.88 | ALDH1A1 (0.44) | NR1H4RARARARBRARGGCK | |
| SCHEMBL17060023 | 0.87 | NR1H4 (0.54) | NR1H4RARARARBRARGGCK | |
| SCHEMBL4276418 | 0.87 | PLA2G2A (0.54) | NR1H4RARARARBRARGGCK | |
| SCHEMBL10068564 | 0.85 | XDH (0.44) | NR1H4RARARARBRARGGCK | |
| SCHEMBL27584673 | 0.84 | TPMT (0.52) | NR1H4RARARARBRARGGCK | |
| SCHEMBL14812140 | 0.81 | RARA (0.49) | NR1H4RARARARBRARGGCK | |
| SCHEMBL1796030 | 0.81 | KMT2A (0.51) | RARARARBRARGGCKMEN1 | |
| SCHEMBL18304457 | 0.80 | XDH (0.36) | NR1H4RARARARBRARGGCK | |
| SCHEMBL2176490 | 0.79 | NR1H4 (0.48) | NR1H4RARARARBRARGGCK | |
| SCHEMBL57366 | 0.78 | RXRA (0.47) | MEN1KMT2ATSHRSMN1; SMN2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-04-16 | — | — | US | disclosed |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | Basilea Pharmaceutica International AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-06-28 | — | — | US | disclosed |
| EP-3307725-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198691-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115339-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | NR1H4 201/4885RARA 2328/4885RARB 2107/4885 |
| US-10464896-B2 | Efflux-pump inhibitors and therapeutic uses thereof | ABCB11, ABCC1, ABCC3 | NR1H4 195/4885RARA 2321/4885RARB 2106/4885 |
| US-20180179158-A1 | EFFLUX-PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCC1, ABCC3 | NR1H4 195/4885RARA 2321/4885RARB 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.